From HandWiki
Short description: Antiarrhythmic medication used for various types of irregular heartbeats
Amiodarone structure.svg
Clinical data
Pronunciation/ˌæmiˈdərn/ or /əˈmdəˌrn/
Trade namesCordarone, Nexterone, Pacerone, others
License data
  • AU: C
Routes of
By mouth, intravenous, intraosseous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding96%
Elimination half-life58 d (range 15–142 d)
ExcretionPrimarily liver and bile
CAS Number
PubChem CID
Chemical and physical data
Molar mass645.320 g·mol−1
3D model (JSmol)

Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of cardiac dysrhythmias.[4] This includes ventricular tachycardia (VT), ventricular fibrillation (VF), and wide complex tachycardia, as well as atrial fibrillation and paroxysmal supraventricular tachycardia.[4] Evidence in cardiac arrest, however, is poor.[5] It can be given by mouth, intravenously, or intraosseously.[4] When used by mouth, it can take a few weeks for effects to begin.[4]

Common side effects include feeling tired, tremor, nausea, and constipation.[4] As amiodarone can have serious side effects, it is mainly recommended only for significant ventricular arrhythmias.[4] Serious side effects include lung toxicity[6] such as interstitial pneumonitis, liver problems, heart arrhythmias, vision problems, thyroid problems, and death.[4] If taken during pregnancy or breastfeeding it can cause problems in the fetus.[4] It is a class III antiarrhythmic medication.[4] It works partly by increasing the time before a heart cell can contract again.[4]

Amiodarone was first made in 1961 and came into medical use in 1962 for chest pain believed to be related to the heart.[7] It was pulled from the market in 1967 due to side effects.[8] In 1974 it was found to be useful for arrhythmias and reintroduced.[8] It is on the World Health Organization's List of Essential Medicines.[9] It is available as a generic medication.[4] In 2020, it was the 198th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[10][11]

Medical uses

Amiodarone has been used both in the treatment of acute life-threatening arrhythmias as well as the long-term suppression of arrhythmias.[12] Amiodarone is commonly used to treat different types of abnormal heart rhythms, such as atrial arrhythmias (supraventricular arrhythmias) and ventricular arrhythmias.[12]

Atrial arrhythmias and supraventricular arrhythmias are terms often used interchangeably to refer to abnormal heart rhythms originating from the upper chambers of the heart, known as the atria. These types of arrhythmias include conditions such as atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia (PSVT). They are collectively referred to as supraventricular or atrial arrhythmias because they occur above (supra) the ventricles in the electrical conduction system of the heart.[13]

Ventricular arrhythmias are abnormal heart rhythms that originate in the ventricles, which are the lower chambers of the heart. These arrhythmias can be potentially life-threatening and may disrupt the heart's ability to pump blood effectively.[13]

Amiodarone can be effective in treating conditions like ventricular fibrillation (a rapid and irregular heartbeat), ventricular tachycardia (fast heartbeat originating from the lower chambers), and cardiac arrest due to shock-resistant ventricular fibrillation.[12]

In cases where a patient is experiencing stable ventricular tachycardia, amiodarone may be used to try to stop the episode. However, recent studies suggest that other antiarrhythmic medications like procainamide may be more effective for this purpose.[12]

Amiodarone is also commonly used as the first-line therapy for patients who receive implantable cardioverter defibrillator (ICD) shocks due to ventricular arrhythmias. Combining amiodarone with beta-blockers has been shown to reduce the likelihood of experiencing appropriate shocks from an ICD.[12]

Cardiac arrest

Defibrillation is the treatment of choice for ventricular fibrillation and pulseless ventricular tachycardia resulting in cardiac arrest. While amiodarone has been used in shock-refractory cases, evidence of benefit is poor.[5] Amiodarone does not appear to improve survival or positive outcomes in those who had a cardiac arrest.[14]

Ventricular tachycardia

Amiodarone may be used in the treatment of ventricular tachycardia in certain instances. Individuals with hemodynamically unstable ventricular tachycardia should not initially receive amiodarone. These individuals should be cardioverted.

Amiodarone can be used in individuals with hemodynamically stable ventricular tachycardia. In these cases, amiodarone can be used regardless of the individual's underlying heart function and the type of ventricular tachycardia; it can be used in individuals with monomorphic ventricular tachycardia, but is contraindicated in individuals with polymorphic ventricular tachycardia as it is associated with a prolonged QT interval which will be made worse with anti-arrhythmic drugs.[15]

Atrial fibrillation

Individuals who have undergone open heart surgery are at an increased risk of developing atrial fibrillation (or AF) in the first few days post-procedure. In the ARCH trial, intravenous amiodarone (2 g administered over 2 d) has been shown to reduce the incidence of atrial fibrillation after open heart surgery when compared to placebo.[16] However, clinical studies have failed to demonstrate long-term efficacy and have shown potentially fatal side effects such as pulmonary toxicities. While amiodarone is not approved for AF by the FDA, it is a commonly prescribed off-label treatment due to the lack of equally effective treatment alternatives.[citation needed]

So-called 'acute onset atrial fibrillation', defined by the North American Society of Pacing and Electrophysiology (NASPE) in 2003, responds well to short-duration treatment with amiodarone. This has been demonstrated in seventeen randomized controlled trials, of which five included a placebo arm. The incidence of severe side effects in this group is low.[citation needed]

The benefit of amiodarone in the treatment of atrial fibrillation in the critical care population has yet to be determined but it may prove to be the agent of choice where the patient is hemodynamically unstable and unsuitable for DC cardioversion. It is recommended in such a role by the UK government's National Institute for Health and Clinical Excellence (NICE).


Women who are pregnant or may become pregnant are strongly advised not to take amiodarone. Since amiodarone can be expressed in breast milk, women taking amiodarone are advised to stop nursing.

It is contraindicated in individuals with sinus nodal bradycardia, atrioventricular block, and second or third-degree heart block who do not have an artificial pacemaker.

Individuals with baseline depressed lung function should be monitored closely if amiodarone therapy is to be initiated.

Formulations of amiodarone that contain benzyl alcohol should not be given to neonates, because the benzyl alcohol may cause the potentially fatal "gasping syndrome".[17]

Amiodarone can worsen the cardiac arrhythmia brought on by digitalis toxicity.

Contraindications of amiodarone also include:

There are no specific guidelines for endurance or high-intensity exercise while taking amiodarone. However, since amiodarone may cause bradycardia and QTc prolongation which can affect exercise capacity and increase the risk of arrhythmias during intense exercise, it would generally be advisable for patients taking this medication to consult their healthcare provider before engaging in high-intensity physical activities such as strenuous endurance exercises.[12]

Side effects

At oral doses of 400 mg per day or higher, amiodarone can have serious, varied side effects, including toxicity to the thyroid gland,[18] liver, lung, and retinal functions, requiring clinical surveillance and regular laboratory testing.[19][20] Allergic reactions to amiodarone may occur.[19] Most individuals administered amiodarone on a chronic basis will experience at least one side effect.[20] In some people, daily use of amiodarone at 100 mg oral doses can be effective for arrhythmia control with no or minimal side effects.[20]

Some common side effects include:

  • nausea and vomiting;[12]
  • taste disturbances (changes in taste perception, often described as a metallic or bitter taste in the mouth);[12]
  • photosensitivity of the skin, also known as photodermatitis, where exposure to sunlight or ultraviolet radiation may lead to skin reactions such as rashes or sunburn-like symptoms;[12]
  • corneal microdeposits (deposits may accumulate on the cornea over time, resulting in visual halos or blurred vision; still, these deposits typically do not affect vision significantly);[12]
  • thyroid dysfunction[21] (in approximately 15-20% of patients, amiodarone treatment results in thyroid dysfunction, either amiodarone-induced hypothyroidism or amiodarone-induced thyrotoxicosis; the drug can lead to both hypo- and hyperthyroidism);[18]
  • pulmonary toxicity[22][23][24][25] (lung problems such as pulmonary fibrosis or interstitial lung disease may occur rarely but have the potential for serious consequences if left untreated);[6][12]
  • liver abnormalities (liver damage, including elevated liver enzymes (AST/ALT) and hepatotoxicity, although severe cases are rare);[12]
  • bradycardia and heart block (since it slows down heart rate by affecting the sinus node function and AV conduction system, it can increase the risk of heart block);[12]
  • QT Interval prolongation.[12]

Amiodarone can potentially cause renal toxicity, but solid studies on whether amiodarone may be toxic to the kidneys are lacking.[26]


A chest X-ray demonstrating pulmonary fibrosis due to amiodarone.

Side effects of oral amiodarone at doses of 400 mg or higher include various pulmonary effects.[27] The most serious reaction is interstitial lung disease. Risk factors include high cumulative dose, more than 400 milligrams per day, duration over two months, increased age, and preexisting pulmonary disease. Some individuals were noted to develop pulmonary fibrosis after a week of treatment, while others did not develop it after years of continuous use.[27] Common practice is to avoid the agent if possible in individuals with decreased lung function.

The most specific test of pulmonary toxicity due to amiodarone is a dramatically decreased DLCO noted on pulmonary function testing.


Induced abnormalities in thyroid function are common.[21][19] In approximately 15-20% of patients, amiodarone treatment results in thyroid dysfunction, either amiodarone-induced hypothyroidism or amiodarone-induced thyrotoxicosis.[18] Both under- and overactivity of the thyroid may occur.[19]

Amiodarone is structurally similar to thyroxine and also contains iodine. Both of these contribute to the effects of amiodarone on thyroid function.[28][29] Amiodarone also causes an anti-thyroid action, via Plummer and Wolff–Chaikoff effects, due its large amount of iodine in its molecule, which causes a particular "cardiac hypothyroidism" with bradycardia and arrhythmia.[30][31]

Thyroid function should be checked at least every six months.[32]

  • Hypothyroidism (slowing of the thyroid) occurs frequently; in the SAFE trial, which compared amiodarone with other medications for the treatment of atrial fibrillation, biochemical hypothyroidism (as defined by a TSH level of 4.5–10 mU/L) occurred in 25.8% of the amiodarone-treated group as opposed to 6.6% of the control group (taking placebo or sotalol). Overt hypothyroidism (defined as TSH >10 mU/L) occurred at 5.0% compared to 0.3%; most of these (>90%) were detected within the first six months of amiodarone treatment.[33]
  • Amiodarone induced thyrotoxicosis (AIT), can be caused due to the high iodine content in the drug via the Jod-Basedow effect. This is known as Type 1 AIT, and usually occurs in patients with an underlying predisposition to hyperthyroidism such as Graves' disease, within weeks to months after starting amiodarone. Type 1 AIT is usually treated with anti-thyroid drugs or thyroidectomy. Type 2 AIT is caused by a destructive thyroiditis due to a direct toxic effect of amiodarone on thyroid follicular epithelial cells. Type 2 AIT can occur even years after starting amiodarone, is usually self-limited and responds to anti-inflammatory treatment such as corticosteroids.[34] In practice, often the type of AIT is undetermined or presumed as mixed with both treatments combined.[34] Thyroid uptake measurements (I-123 or I-131), which are used to differentiate causes of hyperthyroidism, are generally unreliable in patients who have been taking amiodarone. Because of the high iodine content of amiodarone, the thyroid gland is effectively saturated, thus preventing further uptake of isotopes of iodine. However, positive radioactive iodine can be used to rule in type 1AIT .[citation needed]


Corneal micro-deposits (cornea verticillata,[35] also called vortex or whorl keratopathy) are almost universally present (over 90%) in individuals taking amiodarone longer than 6 months, especially doses greater than 400 mg/day. These deposits typically do not cause any symptoms. About 1 in 10 individuals may complain of a bluish halo. Anterior subcapsular lens deposits are relatively common (50%) in higher doses (greater than 600 mg/day) after 6 months of treatment. Optic neuropathy, nonarteritic anterior ischemic optic neuropathy (N-AION), occurs in 1–2% of people and is not dosage dependent.[36] Bilateral optic disc swelling and mild and reversible visual field defects can also occur.

Loss of eyelashes has been linked to amiodarone use.[37]


Abnormal liver enzyme results are common in people taking amiodarone.[19] Much rarer are jaundice, hepatomegaly (liver enlargement), and hepatitis (inflammation of the liver).[38]

Low-dose amiodarone has been reported to cause pseudo-alcoholic cirrhosis.[39][40]


Long-term administration of amiodarone (usually more than eighteen months) is associated with a light-sensitive blue-grey discoloration of the skin, sometimes called ceruloderma; such patients should avoid exposure to the sun and use sunscreen that protects against ultraviolet-A and -B. The discoloration will slowly improve upon cessation of the medication, however, the skin color may not return completely.[41]

Pregnancy and breastfeeding

Use during pregnancy may result in a number of problems in the infant including thyroid problems, heart problems, neurological problems, and preterm birth.[42] Use during breastfeeding is generally not recommended though one dose may be okay.[42]


Long-term use of amiodarone has been associated with peripheral neuropathies.[43]

Amiodarone is sometimes responsible for epididymitis. Amiodarone accumulates in the head of the organ and can cause unilateral or bilateral inflammation. It tends to resolve if amiodarone is stopped.[44]

Some cases of gynecomastia have been reported in men on amiodarone.[45]

A study published in 2013 showed a possible association between amiodarone and an increased risk of cancer, especially in males, with a dose-dependent effect.[46]


The pharmacokinetics of numerous drugs, including many that are commonly administered to individuals with heart disease, are affected by amiodarone. Particularly, doses of digoxin should be halved in individuals taking amiodarone. Amiodarone may also interact with sotalol.[47]

Amiodarone potentiates the action of warfarin by inhibiting the clearance of both (S) and (R) warfarin. Individuals taking both of these medications should have their warfarin doses adjusted based on their dosing of amiodarone and have their anticoagulation status (measured as prothrombin time (PT) and international normalized ratio (INR)) measured more frequently. Dose reduction of warfarin is as follows: 40% reduction if the amiodarone dose is 400 mg daily, 35% reduction if the amiodarone dose is 300 mg daily, 30% reduction if the amiodarone dose is 200 mg daily, and 25% reduction if amiodarone dose is 100 mg daily. The effect of amiodarone on the warfarin concentrations can be as early as a few days after initiation of treatment; however, the interaction may not peak for up to seven weeks.

Amiodarone inhibits the action of the cytochrome P450 isozyme family. This reduces the clearance of many drugs, including the following:

In 2015, Gilead Sciences warned healthcare providers about people who began taking the hepatitis C drugs ledipasvir/sofosbuvir or sofosbuvir along with amiodarone, who developed abnormally slow heartbeats or died of cardiac arrest.[48]

Amiodarone has several interactions with other medications, which can lead to significant changes in drug levels and increase the risk of adverse effects. Here are some important interactions of amiodarone:

  • Class I Antiarrhythmics (amiodarone should not be combined with other class I antiarrhythmic drugs like quinidine, procainamide, or disopyramide due to an increased risk of QTc prolongation and potential arrhythmias);[12]
  • Beta-blockers and Calcium Channel Blockers (combining amiodarone with beta-blockers or calcium channel blockers can further slow down heart rate and cause bradycardia or heart block);[12]
  • Digoxin (amiodarone inhibits a protein called P-glycoprotein (P-gp), which transports digoxin out of cells in the gut, liver, and kidneys, therefore, concurrent use of these medications increases digoxin levels in the body, potentially leading to digoxin toxicity)[12]
  • Statins (amiodarone can inhibit enzymes in the liver responsible for metabolizing certain statins (e.g., simvastatin and atorvastatin), therefore interaction elevates plasma concentrations of these statins, increasing the risk of myopathy (muscle damage) or rhabdomyolysis (severe muscle breakdown))[12]
  • Warfarin (since warfarin anticoagulation depends on metabolism by both cytochromes CYP2C9 and CYP3A4, coadministation leads to rise in international normalized ratio (INR), thereby placing patient at higher bleeding risks)[12]
  • Anti-HIV medications (several HIV medications like ritonavir and indinavir interact with amiodarone by inhibiting CYP3A4 enzyme hence leading to decreased clearance of amiodarone).[12]


Amiodarone is extensively metabolized in the liver by cytochrome P450 3A4 (CYP3A4) and can affect the metabolism of numerous other drugs. It interacts with digoxin, warfarin, phenytoin, and others. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.

On 8 August 2008, the FDA issued a warning of the risk of rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. This interaction is dose-dependent with simvastatin doses exceeding 20 mg. This drug combination, especially with higher doses of simvastatin, should be avoided.[49] Amiodarone is extensively metabolized in the liver. The primary metabolic pathway of amiodarone is by cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2C8.

  • Phase I Metabolism: During phase I metabolism, amiodarone undergoes oxidative processes mainly mediated by CYP3A4 and to a lesser extent by CYP2C8. These reactions result in the formation of several active metabolites, including desethylamiodarone (DEA) and di-desethylamiodarone (DDEA). DEA is the most abundant metabolite and exhibits similar pharmacological effects as amiodarone.
  • Phase II Metabolism: After phase I metabolism, both amiodarone and its major metabolite DEA can undergo conjugation reactions with glucuronic acid during phase II metabolism. This process increases their water solubility for efficient elimination from the body.

Amiodarone has an exceptionally long half-life due to several factors:

  • High Lipid Solubility, given that amiodarone has high lipid solubility, which allows it to distribute throughout various tissues in the body rapidly. Its extensive tissue distribution contributes to a large volume of distribution that leads to slow clearance from plasma compartments.
  • Extensive Tissue Binding, so that amiodarone extensively binds to different tissues, including fat deposits, muscles, heart tissue, and other organs. This tissue binding creates reservoirs where drug release can occur slowly over time, resulting in an extended duration of action even after stopping oral therapy.
  • Prolonged Release Kinetics.

The combination of these factors results in a prolonged elimination half-life for amiodarone.[12]


Excretion is primarily via the liver and the bile duct with almost no elimination via the kidney and it is not dialyzable.[1] Elimination half-life average of 58 days (ranging from 25 to 100 days [Remington: The Science and Practice of Pharmacy 21st edition]) for amiodarone and 36 days for the active metabolite, desethylamiodarone (DEA).[1] There is 10-50% transfer of amiodarone and DEA in the placenta as well as a presence in breast milk.[1] Accumulation of amiodarone and DEA occurs in adipose tissue and highly perfused organs (i.e. liver, lungs),[1] therefore, if an individual was taking amiodarone on a chronic basis if it is stopped it will remain in the system for weeks to months.[1]

Whereas amiodarone is primarily eliminated from the body through hepatic metabolism and biliary excretion, a very small portion of amiodarone and its metabolites are excreted unchanged in urine or feces.

The liver plays a significant role in the elimination of amiodarone. After being extensively metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C8, amiodarone is transported into bile via multidrug-resistant protein 2 (MRP2) transporter. Bile containing amiodarone and its metabolites is then released into the gastrointestinal tract.

Some of these compounds can be reabsorbed back into systemic circulation through enterohepatic recirculation, where they may undergo additional rounds of metabolism before eventually being excreted again into bile.

Although renal excretion contributes only minimally to the elimination of amiodarone, dose adjustment based on kidney function is generally not necessary. This is because most patients with normal renal function can adequately clear the drug through hepatic metabolism and biliary elimination pathways.[12]


Amiodarone is categorized as a class III antiarrhythmic agent, and prolongs phase 3 of the cardiac action potential, the repolarization phase where there is normally decreased calcium permeability and increased potassium permeability. It has numerous other effects, however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV.

Amiodarone is a blocker of voltage gated potassium (KCNH2) and voltage gated calcium channels (CACNA2D2).[50]

Amiodarone slows the conduction rate and prolongs the refractory period of the SA and AV nodes.[51] It also prolongs the refractory periods of the ventricles, bundles of His, and the Purkinje fibers without exhibiting any effects on the conduction rate.[51] Amiodarone has been shown to prolong the myocardial cell action potential duration and refractory period and is a non-competitive β-adrenergic inhibitor.[52]

It also shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects. It is suggested that amiodarone may also exacerbate the phenotype associated with Long QT-3 syndrome causing mutations such as ∆KPQ. This effect is due to a combination of blocking the peak sodium current, but also contributing to an increased persistent sodium current.[53]

Amiodarone chemically resembles thyroxine (thyroid hormone), and its binding to the nuclear thyroid receptor might contribute to some of its pharmacologic and toxic actions.[54] The mechanisms of action of amiodarone include blocking potassium ion channels (prolonging repolarization), blocking sodium ion channels, and antagonizing alpha- and beta-adrenergic receptors.

  • Potassium Channel Blockade: Amiodarone blocks potassium channels involved in cardiac repolarization during phase 3 of the action potential. This prolongs the duration of cardiac action potentials, resulting in an increased refractory period and decreased excitability.
  • Sodium Channel Blockade: By inhibiting sodium ion influx through voltage-gated sodium channels, amiodarone reduces the conduction velocity of electrical impulses in cardiac tissue. This leads to a slowed heart rate and improved rhythm control.
  • Noncompetitive Adrenergic Receptor Antagonism: Amiodarone has both alpha- and beta-adrenergic receptor antagonistic effects, which help reduce sympathetic stimulation on the heart.
  • Calcium Channel Blocking Activity: Amiodarone exhibits calcium channel blockade to some extent by inhibiting L-type calcium channels present in myocardial cells, decreasing intracellular calcium concentration during ventricular contraction.[12]


The original observation that amiodarone's progenitor molecule, khellin, had cardioactive properties, was made by the Russian physiologist Gleb von Anrep while working in Cairo in 1946.[55] Khellin is obtained from a plant extract of Khella or Ammi visnaga, a common plant in north Africa. Anrep noticed that one of his technicians had been cured of anginal symptoms after taking khellin, then used for various, non-cardiac ailments. This led to efforts by European pharmaceutical industries to isolate an active compound.[citation needed] Amiodarone was initially developed in 1961 at the Labaz company, Belgium, by chemists Tondeur and Binon, who were working on preparations derived from khellin. It became popular in Europe as a treatment for angina pectoris.[56][57]

As a doctoral candidate at Oxford University, Bramah Singh determined that amiodarone and sotalol had antiarrhythmic properties and belonged to a new class of antiarrhythmic agents (what would become the class III antiarrhythmic agents).[58] Today the mechanisms of action of amiodarone and sotalol have been investigated in more detail. Both drugs have been demonstrated to prolong the duration of the action potential, prolonging the refractory period, by interacting among other cellular functions with K+ channels.

Based on Singh's work, the Argentina physician Mauricio Rosenbaum began using amiodarone to treat his patients who have supraventricular and ventricular arrhythmias, with impressive results. Based on papers written by Rosenbaum developing Singh's theories, physicians in the United States began prescribing amiodarone to their patients with potentially life-threatening arrhythmias in the late 1970s.[59][60] By 1980, amiodarone was commonly prescribed throughout Europe for the treatment of arrhythmias, but in the U.S. amiodarone remained unapproved by the Food and Drug Administration, and physicians were forced to directly obtain amiodarone from pharmaceutical companies in Canada and Europe.[citation needed]

The FDA was reluctant to officially approve the use of amiodarone since initial reports had shown an increased incidence of serious pulmonary side effects of the drug. In the mid-1980s, the European pharmaceutical companies began putting pressure on the FDA to approve amiodarone by threatening to cut the supply to American physicians if it was not approved. In December 1985, amiodarone was approved by the FDA for the treatment of arrhythmias.[2][61] This makes amiodarone one of the few drugs approved by the FDA without rigorous randomized clinical trials.[citation needed]


Amiodarone may be an acronym[citation needed] for its IUPAC name (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone,[62] where ar is a placeholder for phenyl. This is partially supported by dronedarone which is noniodinated benzofuran derivative of amiodarone, where the arylmethanone is conserved.[citation needed]


Amiodarone is available in oral and intravenous formulations.

Orally, it is available under the brand names Pacerone (produced by Upsher-Smith Laboratories, Inc.) and Cordarone (produced by Wyeth-Ayerst Laboratories).[1][2] It is also available under the brand name Aratac (produced by Alphapharm Pty Ltd) in Australia and New Zealand, and further in Australia under the brands Cardinorm and Rithmik as well as a number of generic brands. Also Arycor in South Africa (Produced by Winthrop Pharmaceuticals.). In South America, it is known as Atlansil and is produced by Roemmers.

In India, amiodarone is marketed (produced by Cipla Pharmaceutical) under the brand name Tachyra. It is also available in intravenous ampules and vials.

The dose of amiodarone administered is tailored to the individual and the dysrhythmia that is being treated. When administered orally, the bioavailability of amiodarone is quite variable. Absorption ranges from 22 to 95%, with better absorption when it is given with food.[63]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Pacerone- amiodarone hydrochloride tablet". 
  2. 2.0 2.1 2.2 "Cordarone (amiodarone) tablets, for oral use Initial U.S. Approval: 1985". 30 October 2018. 
  3. "Nexterone- Amiodarone HCl injection, solution". 
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 "Amiodarone Hydrochloride". The American Society of Health-System Pharmacists. 
  5. 5.0 5.1 "Effectiveness of antiarrhythmic drugs for shockable cardiac arrest: A systematic review". Resuscitation 132: 63–72. November 2018. doi:10.1016/j.resuscitation.2018.08.025. PMID 30179691. 
  6. 6.0 6.1 "Acute Amiodarone Pulmonary Toxicity". J Cardiothorac Vasc Anesth 35 (5): 1485–1494. May 2021. doi:10.1053/j.jvca.2020.10.060. PMID 33262034. 
  7. (in en) Analytical Profiles of Drug Substances and Excipients. Academic Press. 1992. p. 4. ISBN 9780080861159. 
  8. 8.0 8.1 (in en) Analogue-based Drug Discovery. John Wiley & Sons. 2005. p. 12. ISBN 9783527607495. 
  9. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO. 
  10. "The Top 300 of 2020". 
  11. "Amiodarone – Drug Usage Statistics". 
  12. 12.00 12.01 12.02 12.03 12.04 12.05 12.06 12.07 12.08 12.09 12.10 12.11 12.12 12.13 12.14 12.15 12.16 12.17 12.18 12.19 12.20 12.21 12.22 12.23 12.24 12.25 12.26 12.27 "Amiodarone: A Comprehensive Guide for Clinicians". Am J Cardiovasc Drugs 20 (6): 549–558. December 2020. doi:10.1007/s40256-020-00401-5. PMID 32166725. 
  13. 13.0 13.1 "What is the real cardiac anatomy?". Clin Anat 32 (3): 288–309. April 2019. doi:10.1002/ca.23340. PMID 30675928. 
  14. "Amiodarone and cardiac arrest: Systematic review and meta-analysis". International Journal of Cardiology 221: 780–788. October 2016. doi:10.1016/j.ijcard.2016.07.138. PMID 27434349. 
  15. Resuscitation Council (UK) Peri-arrest arrhythmias – Tachycardia algorithm Retrieved 25 January 2016
  16. "Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial". Journal of the American College of Cardiology 34 (2): 343–347. August 1999. doi:10.1016/S0735-1097(99)00212-0. PMID 10440143. 
  17. Centers for Disease Control (CDC) (June 1982). "Neonatal deaths associated with use of benzyl alcohol--United States". MMWR. Morbidity and Mortality Weekly Report 31 (22): 290–291. PMID 6810084. 
  18. 18.0 18.1 18.2 "Short review: novel concepts in the approach to patients with amiodarone-induced thyrotoxicosis". J Endocrinol Invest. September 2023. doi:10.1007/s40618-023-02168-3. PMID 37731073. 
  19. 19.0 19.1 19.2 19.3 19.4 "Amiodarone". 18 May 2022. 
  20. 20.0 20.1 20.2 "Low-dose Amiodarone Is Safe: A Systematic Review and Meta-analysis". The Journal of Innovations in Cardiac Rhythm Management 11 (4): 4054–4061. April 2020. doi:10.19102/icrm.2020.110403. PMID 32368381. 
  21. 21.0 21.1 "When amiodarone-induced thyroiditis meets cardiomyopathy with excessive trabeculation: a case report". Front Cardiovasc Med 10: 1212965. 2023. doi:10.3389/fcvm.2023.1212965. PMID 37547257. 
  22. "Amiodarone-Induced Lung Toxicity: A Case Initially Not Correctly Framed". Cureus 15 (3): e36818. March 2023. doi:10.7759/cureus.36818. PMID 37123694. 
  23. "Variable radiographic and histologic presentations of amiodarone-related interstitial lung disease and the importance of avoiding re-exposure". Respirol Case Rep 11 (6): e01165. June 2023. doi:10.1002/rcr2.1165. PMID 37249923. 
  24. "Pulmonary Fibrosis Related to Amiodarone-Is It a Standard Pathophysiological Pattern? A Case-Based Literature Review". Diagnostics 12 (12): 3217. December 2022. doi:10.3390/diagnostics12123217. PMID 36553223. 
  25. "Amiodarone induced lung disease". Arch Clin Cases 9 (3): 126–132. 2022. doi:10.22551/2022.36.0903.10217. PMID 36176494. 
  26. "Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis". Eur Heart J Case Rep 7 (9): ytad457. September 2023. doi:10.1093/ehjcr/ytad457. PMID 37743903. 
  27. 27.0 27.1 "Amiodarone Side Effects". 25 April 2021. 
  28. "Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis". The Journal of Clinical Endocrinology and Metabolism 100 (1): E1-10. January 2015. doi:10.1210/jc.2014-2745. PMID 25295624. 
  29. (in en) Core Topics in Endocrinology in Anaesthesia and Critical Care. Cambridge University Press. 2010. p. 170. ISBN 9781139486125. 
  30. "Evolutionary Significance of Iodine". Current Chemical Biology 5 (3): 155–162. 2011. doi:10.2174/187231311796765012. ISSN 1872-3136. 
  31. "Iodine, PUFAs and Iodolipids in Health and Disease: An Evolutionary Perspective". Human Evolution 29 (1–3): 185–205. 2014. ISSN 0393-9375. 
  32. "2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction". European Thyroid Journal 7 (2): 55–66. March 2018. doi:10.1159/000486957. PMID 29594056. 
  33. "Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation". The American Journal of Medicine 120 (10): 880–885. October 2007. doi:10.1016/j.amjmed.2007.04.022. PMID 17904459. 
  34. 34.0 34.1 "Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders". The Journal of Clinical Endocrinology and Metabolism 106 (1): 226–236. January 2021. doi:10.1210/clinem/dgaa686. PMID 33159436. 
  35. "Amiodarone-induced cornea verticillata". Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie 17 (3): 96–99. June 1982. PMID 7116220. 
  36. "Amiodarone-associated optic neuropathy: a critical review". The American Journal of Medicine 125 (5): 447–453. May 2012. doi:10.1016/j.amjmed.2011.09.020. PMID 22385784. 
  37. Ocular differential diagnosis (9th ed.). Panama City, Panama: Jaypee Highlights Medical Publishers. 2012. p. 94. ISBN 9789350255711. 
  38. "Hepatotoxicity associated with amiodarone therapy". Pharmacotherapy 9 (1): 39–44. 1989. doi:10.1002/j.1875-9114.1989.tb04102.x. PMID 2646621. 
  39. "Low dose amiodarone causing pseudo-alcoholic cirrhosis". Age and Ageing 32 (2): 224–225. March 2003. doi:10.1093/ageing/32.2.224. PMID 12615569. 
  40. "Hepatic cirrhosis caused by low-dose oral amiodarone therapy". The American Journal of the Medical Sciences 330 (5): 257–261. November 2005. doi:10.1097/00000441-200511000-00012. PMID 16284489. 
  41. "Skin Discoloration from Amiodarone". The New England Journal of Medicine 382 (3): e5. January 2020. doi:10.1056/NEJMicm1906774. PMID 31940702. 
  42. 42.0 42.1 "Amiodarone Pregnancy and Breastfeeding Warnings" (in en). 
  43. "Peripheral neuropathy during long-term high-dose amiodarone therapy". Journal of Neurology, Neurosurgery, and Psychiatry 48 (6): 576–578. June 1985. doi:10.1136/jnnp.48.6.576. PMID 2989436. 
  44. "Urologic complications of neurologic medications". The Urologic Clinics of North America 30 (1): 123–131. February 2003. doi:10.1016/S0094-0143(02)00111-8. PMID 12580564. 
  45. [1] Gynecomastia: Its features, and when and how to treat it
  46. "Amiodarone and the risk of cancer: a nationwide population-based study". Cancer 119 (9): 1699–1705. May 2013. doi:10.1002/cncr.27881. PMID 23568847. 
  47. "Amiodarone and sotalol Drug Interactions" (in en). 
  48. West, Stephen. "Gilead Warns After Hepatitis Patient on Heart Drug Dies" . Published 21 March 2015.
  49. "Information on Simvastatin/Amiodarone". 
  50. "Amiodarone". Drugbank. 
  51. 51.0 51.1 Amiodarone: pharmacology, pharmacokinetics, toxicology, clinical effects. Paris: Médecine et sciences internationales. 1986. p. 12. ISBN 2864391252. 
  52. "FDA Drug Label". 
  53. "Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels". Frontiers in Pharmacology 7: 39. 2016. doi:10.3389/fphar.2016.00039. PMID 26973526. 
  54. Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. 2005. ISBN 0-07-142280-3. [page needed]
  55. "Ammi Visnaga in the Treatment of the Anginal Syndrome". British Heart Journal 8 (4): 171–177. October 1946. doi:10.1136/hrt.8.4.171. PMID 18610042. 
  56. "[Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran]" (in fr). Archives Internationales de Pharmacodynamie et de Therapie 139: 247–254. September 1962. PMID 14026835. 
  57. "[Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran]" (in fr). Archives Internationales de Pharmacodynamie et de Therapie 139: 255–264. September 1962. PMID 14020244. 
  58. "The effect of amiodarone, a new anti-anginal drug, on cardiac muscle". British Journal of Pharmacology 39 (4): 657–667. August 1970. doi:10.1111/j.1476-5381.1970.tb09891.x. PMID 5485142. 
  59. "Clinical efficacy of amiodarone as an antiarrhythmic agent". The American Journal of Cardiology 38 (7): 934–944. December 1976. doi:10.1016/0002-9149(76)90807-9. PMID 793369. 
  60. "Ten years of experience with amiodarone". American Heart Journal 106 (4 Pt 2): 957–964. October 1983. doi:10.1016/0002-8703(83)90022-4. PMID 6613843. 
  61. "Drug Approval Package: Cordarone (Amiodarone Hydrochloride) Tablets. NDA #018972". U.S. Food and Drug Administration. 
  62. "Compound summary for CID 2157". 
  63. "Amiodarone: guidelines for use and monitoring". American Family Physician 68 (11): 2189–2196. December 2003. PMID 14677664.